Accendra Health Inc reports results for the quarter ended June 30 - Earnings Summary
Accendra Health Inc reports results for the quarter ended June 30 - Earnings Summary
Accendra Health Inc ACH.N reported a quarterly adjusted loss of 19 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 26 cents. The mean expectation of six analysts for the quarter was for a loss of 9 cents per share. Wall Street expected results to range from -17 cents to 1 cents per share.
Revenue fell 10.1% to $613.23 million from a year ago; analysts expected $627.31 million.
Accendra Health Inc's reported EPS for the quarter was a loss of $1.16.
The company reported a quarterly loss of $89.07 million.
Accendra Health Inc shares had fallen by 18.1% this quarter and held steady so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 34.5% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Accendra Health Inc is $4.50, about 37.8% above its last closing price of $2.80
This summary was machine generated from LSEG data August 10 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.09 | -0.19 | Missed |
Mar. 31 2026 | -0.10 | -0.04 | Beat |
Dec. 31 2025 | 0.22 | 0.21 | Missed |
Sep. 30 2025 | 0.23 | 0.25 | Beat |
Recent news on Accendra Health
See all newsBrief: Accendra Health Receives Continued Listing Standard Notice From NYSE
Brief: Accendra Health Names Kenneth Gardner-Smith As President And Chief Executive Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Accendra Health Inc reports results for the quarter ended June 30 - Earnings Summary
Accendra Health Q2 profit, revenue miss estimates on large payor exit